Literature DB >> 9572795

Acetylcholine and substance P stimulate bronchial epithelial cells to release eosinophil chemotactic activity.

S Koyama1, E Sato, H Nomura, K Kubo, S Nagai, T Izumi.   

Abstract

We investigated a role of neuroregulation in the release of eosinophil chemotactic activity (ECA) from bovine bronchial epithelial cells (BBEC). BBEC were stimulated with acetylcholine (ACh) and substance P (SP), and the supernatant fluids were tested for ECA by a blind-well chemotactic chamber technique. BBEC released ECA in response to ACh and SP in a dose- and time-dependent manner. Checkerboard analysis showed that ECA in regard to ACh and SP was chemotactic rather than chemokinetic. Partial characterization revealed that ECA involved both lipids and peptides. The release of ECA in response to ACh and SP was inhibited by nonspecific and 5-specific lipoxygenase inhibitors and by cycloheximide (P < 0.01). Molecular-sieve column chromatography revealed that these mediators induced three molecular mass peaks (near 25 kDa, 9 kDa, and 400 Da, respectively). The lowest peak, which represented the predominant activity, was blocked by leukotriene B4-receptor antagonist (P < 0. 01) but not by platelet-activating factor-receptor antagonist. The release of leukotriene B4 in the supernatant fluids was increased in response to ACh and SP stimulation (P < 0.01). Platelet-activating factor was not detected. These results raise the possibility of a role of neuroregulation for the elaboration of ECA in the airway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9572795     DOI: 10.1152/jappl.1998.84.5.1528

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  14 in total

Review 1.  Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.

Authors:  Martin S Steinhoff; Bengt von Mentzer; Pierangelo Geppetti; Charalabos Pothoulakis; Nigel W Bunnett
Journal:  Physiol Rev       Date:  2014-01       Impact factor: 37.312

2.  Non-bronchodilating mechanisms of tiotropium prevent airway hyperreactivity in a guinea-pig model of allergic asthma.

Authors:  K S Buels; D B Jacoby; A D Fryer
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  Muscarinic receptor antagonists: effects on pulmonary function.

Authors:  Kalmia S Buels; Allison D Fryer
Journal:  Handb Exp Pharmacol       Date:  2012

4.  Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism.

Authors:  John Meshki; Steven D Douglas; Jian-Ping Lai; Lynnae Schwartz; Laurie E Kilpatrick; Florin Tuluc
Journal:  J Biol Chem       Date:  2009-01-28       Impact factor: 5.157

Review 5.  Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases.

Authors:  Khuder Alagha; Alain Palot; Tunde Sofalvi; Laurie Pahus; Marion Gouitaa; Celine Tummino; Stephanie Martinez; Denis Charpin; Arnaud Bourdin; Pascal Chanez
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

6.  Unilateral nasal allergic reactions increase bilateral sinus eosinophil infiltration.

Authors:  Fuad M Baroody; Marcella Detineo; Robert M Naclerio
Journal:  J Appl Physiol (1985)       Date:  2013-08-22

7.  Inhibition of granulocyte migration by tiotropium bromide.

Authors:  Gabriela Vacca; Winfried J Randerath; Adrian Gillissen
Journal:  Respir Res       Date:  2011-02-27

8.  Cholinergic regulation of airway inflammation and remodelling.

Authors:  Saeed Kolahian; Reinoud Gosens
Journal:  J Allergy (Cairo)       Date:  2012-01-16

Review 9.  The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.

Authors:  Marisa Rosso; Miguel Muñoz; Michael Berger
Journal:  ScientificWorldJournal       Date:  2012-04-01

Review 10.  Penehyclidine hydrochloride: a potential drug for treating COPD by attenuating Toll-like receptors.

Authors:  Hong-Tao Xiao; Zhi Liao; Rong-Sheng Tong
Journal:  Drug Des Devel Ther       Date:  2012-11-01       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.